For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of GeneDx Holdings Corp (NASDAQ: WGS) was $131.5 for the day, down -0.20% from the previous closing price of $131.76. In other words, the price has decreased by -$0.20 from its previous closing price. On the day, 0.64 million shares were traded. WGS stock price reached its highest trading level at $136.74 during the session, while it also had its lowest trading level at $128.75.
Ratios:
Our analysis of WGS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 24.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 245.70. For the most recent quarter (mrq), Quick Ratio is recorded 2.59 and its Current Ratio is at 2.71. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on October 20, 2025, initiated with a Buy rating and assigned the stock a target price of $155.
On July 09, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $110.
On May 15, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $88.Guggenheim initiated its Buy rating on May 15, 2025, with a $88 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 30 ’25 when Stueland Katherine sold 12,858 shares for $108.17 per share. The transaction valued at 1,390,911 led to the insider holds 1,720 shares of the business.
Feeley Kevin sold 6,609 shares of WGS for $716,261 on Sep 30 ’25. The CHIEF FINANCIAL OFFICER now owns 3,392 shares after completing the transaction at $108.38 per share. On Sep 30 ’25, another insider, Kevin Feeley, who serves as the Officer of the company, bought 5,805 shares for $107.73 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WGS now has a Market Capitalization of 3800953600 and an Enterprise Value of 3744983552. As of this moment, GeneDx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2180.76, and their Forward P/E ratio for the next fiscal year is 143.79. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 21.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.45 while its Price-to-Book (P/B) ratio in mrq is 13.00. Its current Enterprise Value per Revenue stands at 9.311 whereas that against EBITDA is 107.872.
Stock Price History:
The Beta on a monthly basis for WGS is 2.07, which has changed by 0.69153583 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, WGS has reached a high of $146.00, while it has fallen to a 52-week low of $55.17. The 50-Day Moving Average of the stock is 6.11%, while the 200-Day Moving Average is calculated to be 37.90%.
Shares Statistics:
WGS traded an average of 643.45K shares per day over the past three months and 708080 shares per day over the past ten days. A total of 28.89M shares are outstanding, with a floating share count of 25.33M. Insiders hold about 12.35% of the company’s shares, while institutions hold 109.29% stake in the company. Shares short for WGS as of 1760486400 were 3000341 with a Short Ratio of 4.66, compared to 1757894400 on 3610151. Therefore, it implies a Short% of Shares Outstanding of 3000341 and a Short% of Float of 20.94.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of GeneDx Holdings Corp (WGS).The consensus estimate for the next quarter is $0.43, with high estimates of $0.6 and low estimates of $0.28.
Analysts are recommending an EPS of between $2.05 and $1.56 for the fiscal current year, implying an average EPS of $1.8. EPS for the following year is $2.57, with 6.0 analysts recommending between $3.28 and $2.21.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $122.1M to a low estimate of $120.3M. As of. The current estimate, GeneDx Holdings Corp’s year-ago sales were $95.64MFor the next quarter, 5 analysts are estimating revenue of $112.04M. There is a high estimate of $119.8M for the next quarter, whereas the lowest estimate is $91.7M.
A total of 5 analysts have provided revenue estimates for WGS’s current fiscal year. The highest revenue estimate was $428.7M, while the lowest revenue estimate was $426.8M, resulting in an average revenue estimate of $427.46M. In the same quarter a year ago, actual revenue was $305.45MBased on 9 analysts’ estimates, the company’s revenue will be $513.79M in the next fiscal year. The high estimate is $545.6M and the low estimate is $475M.
